AstraZeneca faces legal challenge over Covid vaccine | WPN World People News

AstraZeneca is facing legal action over its Covid vaccine, initiated by a man who suffered severe brain injury after receiving the jab in April 2021. Jamie Scott, a father-of-two, experienced a blood clot that left him with brain damage and unable to continue working. The legal action, taken under the Consumer Protection Act, alleges that the vaccine was "defective" as it was less safe than individuals were entitled to expect. While Covid vaccines have saved millions of lives, this particular case highlights concerns related to blood clots and brain hemorrhages associated with the AstraZeneca vaccine¹.

During the Covid pandemic, the AstraZeneca vaccine was initially hailed by then-UK Prime Minister Boris Johnson as a "triumph of British science," saving at least six million lives in its first year. However, it was later found to be linked to a new condition called "Vaccine-induced immune thrombotic thrombocytopenia" (VITT). Consequently, the UK recommended alternative vaccines for individuals under 40, and the AstraZeneca vaccine is no longer in use there. Legal experts criticize AstraZeneca for its handling of medical terminology related to TTS (Thrombosis with Thrombocytopenia Syndrome) and VITT. Interestingly, the US Centers for Disease Control and Prevention (CDC) considers both conditions to be the same¹.

Data from the UK's Medicines & Healthcare products Regulatory Agency (MHRA) indicates at least 81 deaths suspected to be related to blood clot adverse reactions in individuals with pre-existing low platelet counts who received the AstraZeneca vaccine. According to MHRA data, nearly 20% of patients who experienced blood clots after receiving the vaccine resulted in fatalities¹.

The Daily Telegraph reports that AstraZeneca's acknowledgment of the relationship between the vaccine and adverse effects significantly increases the chances of success for the plaintiffs. The UK courts have received 51 similar lawsuits seeking compensation totaling up to £100 million. AstraZeneca, as the UK's second-largest publicly traded company, has a market value exceeding £170 billion¹.

Please note that this translation is based on the provided news content, and I recommend referring to the original source for further details¹.